ISOCHROMOSOME-17Q IN A CASE OF MYELOFIBROSIS WITH MYELOID METAPLASIA TERMINATING IN BLASTIC TRANSFORMATION

被引:6
作者
NAKAMURA, H
SADAMORI, N
YAMADA, Y
YAO, EI
TAGAWA, M
NISHINO, K
SASAGAWA, I
KAMIHIRA, S
OYAKAWA, Y
TOMONAGA, M
ICHIMARU, M
机构
关键词
D O I
10.1016/0165-4608(87)90102-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A case of myelofibrosis with myeloid metaplasia in a 61-year-old female patient is reported. Cytogenetic studies were performed using short-term culture without phytohemagglutinin. A chromosomal aberration of an isochromosome 17q, [i(17q)], was revealed in 88% of the metaphases of peripheral blood cells in the blastic phase. However, all metaphases of bone marrow cells in the chronic phase showed a normal karyotype. Furthermore, i(17q) was also observed in 10% of the metaphases of spleen cells examined 8 months before blastic transformation. In this case, therefore, the cells with i(17q) were associated with an abnormal clone of blastic transformation, with the abnormal clone originating in the spleen with myeloid metaplasia.
引用
收藏
页码:221 / 224
页数:4
相关论文
共 13 条
[1]  
AKAHOSHI M, 1984, JAPAN J CLIN HEMATOL, V25, P352
[2]  
BARAVIKA I, 1980, FOLIA HEMATOL LEIPZI, V6, P885
[3]   ABNORMALITIES OF CHROMOSOME NO-17 IN MYELOPROLIFERATIVE DISORDERS [J].
BORGSTROM, GH ;
VUOPIO, P ;
DELACHAPELLE, A .
CANCER GENETICS AND CYTOGENETICS, 1982, 5 (02) :123-135
[4]   MYELOFIBROSIS CLINICAL, HEMATOLOGIC AND PATHOLOGIC STUDY OF 110 PATIENTS [J].
BOURONCLE, BA ;
DOAN, CA .
AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 1962, 243 (06) :697-&
[5]  
CEHRELI C, 1976, CANCER-AM CANCER SOC, V38, P1297, DOI 10.1002/1097-0142(197609)38:3<1297::AID-CNCR2820380332>3.0.CO
[6]  
2-4
[7]  
HOSSFELD DK, 1973, CHEMOTHERAPY CANCER
[8]  
JENSEN MK, 1973, ACTA MED SCAND, P353
[9]  
MITELMAN F, 1974, SCAND J HAEMATOL, V13, P87
[10]   CLONAL EVOLUTION OF MARKER CHROMOSOMES IN A CASE OF MYELOFIBROSIS WITH MYELOID METAPLASIA AND MYELOBLASTIC TRANSFORMATION [J].
PAGE, BM ;
WATT, JL ;
REID, IN ;
DAVIDSON, RJL ;
WALKER, W .
ACTA HAEMATOLOGICA, 1979, 61 (06) :301-309